CareDx (CDNA) Stock: Buy, Sell, or Hold?
CDNA - CareDx, Inc.
$50.26
0.24 (0.48%)
â˛
5d:
+0.8%
30d:
+6.24%
90d:
+112.43%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When CDNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CDNA is fairly priced but lacks strong directional signals. At 17.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CDNA is fairly priced but lacks strong directional signals. At 17.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.68
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$27.12
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 23.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CDNA is currently trading at $50.26, which is considered slightly high relative to its 30-day fair value range of $46.33 to $50.25. From a valuation perspective, the stock is trading at a premium (Forward PE: 37.6) compared to its historical average (23.3). At these levels, the market is pricing in 17.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDNA is in a strong uptrend. Immediate support is located at $46.69, while resistance sits at $52.38.
Market Sentiment: CDNA scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CDNA is in a strong uptrend. Immediate support is located at $46.69, while resistance sits at $52.38.
Market Sentiment: CDNA scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$46.33 -
$50.25
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
37.1%
Protect Your Profits
Holding CDNA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (21/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($54.14)
- NEUTRAL: Trading at premium valuation - market expects 17.3% growth which is achievable
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$46.33 -
$50.25
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$46.69
Resistance Level
$52.38
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
37.65
Wall Street Target
$54.14
(+8.2%)
Revenue Growth (YoY)
52.2%
Profit Margin
24.2%
Valuation Premium vs History
+17.3% premium
PE vs Historical
37.7 vs 23.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+17.3%
(market-implied from PE analysis)
1-Year Target
$58.67
(+17%)
2-Year Target
$68.82
(+38%)
3-Year Target
$80.73
(+61%)
3-Yr Target (if PE normalizes)
(PE: 38â23)
PE COMPRESSION
$49.96
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 37.6, Growth: 10.3%)
$67.16
(+34%)
Base:
(SPY PE: 20.2, Growth: 10.3%)
$35.98
(-28%)
Bear:
(PE: 17.1, Growth: 10.3%)
$30.58
(-39%)
đ
Valuation based on Current Earnings
Trailing PE: 24.17 | Current EPS (TTM): $2.07
Bull Case
$35.32
(-29%)
Analyst growth -35.8%, PE expands to 26.6
Base Case
$32.11
(-36%)
Market implied -35.8%, PE stable at 24.2
Bear Case
$34.02
(-32%)
Severe decline -20.0%, PE contracts to 20.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 11, 2026 4:06 PM ET
Data refreshes hourly during market hours. Next update: 5:06 PM
Data refreshes hourly during market hours. Next update: 5:06 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
John Walter Hanna Jr
SELL
10282 shares
2026-04-16
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$638 | 51 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$229 | 49 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 49 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$338 | 47 HOLD |
Advanced CDNA Option Strategies
Professional options setups generated by AI based on today's CDNA price and gamma walls.
